Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - olive oil, quantity: 32 g/l; soya oil, quantity: 8 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; water for injections; sodium hydroxide; egg lecithin; nitrogen; glycerol - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - soya oil, quantity: 8 g/l; olive oil, quantity: 32 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; nitrogen; egg lecithin; glycerol; sodium oleate - olimel/periolimel is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 990 mg in 100 ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77) - isoleucine 462 mg in 100 ml

Združene države Amerike - angleščina - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 534 mg in 100 ml - aminosyn-pf 7%, sulfite-free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with aminosyn-pf 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. see dosage and administration for additional information. central

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine,arginine,aspartic acid,calcium chloride dihydrate,glucose monohydrate,glutamic acid,glycine,histidine,isoleucine,leucine,lysine hydrochloride,magnesium sulfate heptahydrate,methionine,phenylalanine,potassium chloride,proline,serine,sodium acetate trihydrate,sodium glycerophosphate,soya oil,threonine,tryptophan,tyrosine,valine -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - alanine, quantity: 16 g/l; glycylglutamine monohydrate, quantity: 30.27 g/l (equivalent: glutamine, qty 20 g); histidine, quantity: 6.8 g/l; methionine, quantity: 5.6 g/l; tryptophan, quantity: 1.9 g/l; threonine, quantity: 5.6 g/l; lysine acetate, quantity: 12.7 g/l (equivalent: glycine, qty 10.27 g; equivalent: lysine, qty 9 g); valine, quantity: 7.3 g/l; arginine, quantity: 11.3 g/l; glycyltyrosine dihydrate, quantity: 3.45 g/l (equivalent: tyrosine, qty 2.28 g; equivalent: glycine, qty 0.94 g); serine, quantity: 4.5 g/l; proline, quantity: 6.8 g/l; glutamic acid, quantity: 5.6 g/l; leucine, quantity: 7.9 g/l; isoleucine, quantity: 5.6 g/l; aspartic acid, quantity: 3.4 g/l; phenylalanine, quantity: 5.85 g/l - injection, intravenous infusion - excipient ingredients: water for injections; citric acid - glamin provides amino acids as part of parenteral nutrition therapy, when oral or enteral nutrition is impossible, insufficient or contraindicated especially in patients with a moderate or severe catabolic status.

Malta - angleščina - Medicines Authority

fresenius kabi limited - phenylalanine; arginine; aspartic acid; alanine; threonine; valine; glutamic acid; glycine; isoleucine; l-lysine; l-methionine; l-tryptophan; l-tyrosine; serine; l-cysteine; leucine; l-histidine; proline - solution for infusion - phenylalanine 7.9 g/l; arginine 11.3 g/l; aspartic acid 3.4 g/l; alanine 16 g/l; threonine 5.6 g/l; valine 7.3 g/l; glutamic acid 5.6 g/l; glycine 7.9 g/l; isoleucine 5.6 g/l; l-lysine 9 g/l; l-methionine 5.6 g/l; l-tryptophan 1.9 g/l; l-tyrosine 230 mg/l; serine 4.5 g/l; l-cysteine 560 mg/g; leucine 7.9 g/l; l-histidine 6.8 g/l; proline 6.8 g/l - blood substitutes and perfusion solutions

Združene države Amerike - angleščina - NLM (National Library of Medicine)

b. braun medical inc. - lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), alanine (unii: of5 - lysine 1.18 g in 100 ml - plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. this use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: —   gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; —   bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; —   tube feeding methods alone cannot provide adequate nutrition. this solution should not be used in patients in hepatic coma, severe renal failure, metabolic disorders involving impaired nitrogen utilization or hypersensitivity to one or more amino acids.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), cysteine hydrochlo - isoleucine 0.49 g in 100 ml - trophamine® is indicated for the nutritional support of infants (including those of low birth weight) and young pediatric patients requiring tpn via either central or peripheral infusion routes. parenteral nutrition with trophamine® is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings , precautions, pediatric use , and dosage and administration . central venous infusion should b